Glaucoma

Studies from P. Gouws and colleagues reveal new findings on glaucoma

Published in MD Week, December 28th, 2007

According to recent research from Hastings, the United Kingdom, "Data are provided from the Combigan Early Experience Data (CEED) study, which evaluated patients' clinical experience of using Combigan (R) in a real-life setting. CEED was a Canadian open-label, prospective 2-month surveillance trial involving 47 investigators and 453 patients."

"Primary outcomes were intraocular pressure (IOP) reduction and patient satisfaction. Adverse events and doctor satisfaction were secondary outcomes. Most patients were aged over 50, with 82% white, and nearly 90% had open-angle glaucoma. Combigan was used either as a replacement of, or an addition to, the patients' existing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of MD Week

Source: MD Week (2007-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry